[go: up one dir, main page]

WO2004048541A3 - Cct6s as modifiers of the rb pathway and methods of use - Google Patents

Cct6s as modifiers of the rb pathway and methods of use Download PDF

Info

Publication number
WO2004048541A3
WO2004048541A3 PCT/US2003/037548 US0337548W WO2004048541A3 WO 2004048541 A3 WO2004048541 A3 WO 2004048541A3 US 0337548 W US0337548 W US 0337548W WO 2004048541 A3 WO2004048541 A3 WO 2004048541A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
cct6s
modifiers
cct6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/037548
Other languages
French (fr)
Other versions
WO2004048541A2 (en
Inventor
Albert K Tai
Chunyan Song
Michael Martin Ollmann
Lucile A Gillett
Kim Lickteig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to JP2004555682A priority Critical patent/JP4646631B2/en
Priority to CA002506686A priority patent/CA2506686A1/en
Priority to EP03789986A priority patent/EP1578945A4/en
Priority to AU2003294501A priority patent/AU2003294501B2/en
Publication of WO2004048541A2 publication Critical patent/WO2004048541A2/en
Anticipated expiration legal-status Critical
Publication of WO2004048541A3 publication Critical patent/WO2004048541A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G01N33/57557—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human CCT6 genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of CCT6 are provided.
PCT/US2003/037548 2002-11-25 2003-11-24 Cct6s as modifiers of the rb pathway and methods of use Ceased WO2004048541A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004555682A JP4646631B2 (en) 2002-11-25 2003-11-24 CCT6s as RB pathway modifiers and methods of use
CA002506686A CA2506686A1 (en) 2002-11-25 2003-11-24 Cct6s as modifiers of the rb pathway and methods of use
EP03789986A EP1578945A4 (en) 2002-11-25 2003-11-24 CCT6 AS MODIFIERS OF THE RB PATHWAY AND CORRESPONDING METHODS OF USE
AU2003294501A AU2003294501B2 (en) 2002-11-25 2003-11-24 CCT6S as modifiers of the RB pathway and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US60/428,872 2002-11-25

Publications (2)

Publication Number Publication Date
WO2004048541A2 WO2004048541A2 (en) 2004-06-10
WO2004048541A3 true WO2004048541A3 (en) 2005-08-18

Family

ID=32393472

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/037538 Ceased WO2004048536A2 (en) 2002-11-25 2003-11-24 Rhebs as modifiers of the rb pathway and methods of use
PCT/US2003/037548 Ceased WO2004048541A2 (en) 2002-11-25 2003-11-24 Cct6s as modifiers of the rb pathway and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037538 Ceased WO2004048536A2 (en) 2002-11-25 2003-11-24 Rhebs as modifiers of the rb pathway and methods of use

Country Status (5)

Country Link
EP (1) EP1578945A4 (en)
JP (1) JP4646631B2 (en)
AU (2) AU2003294499A1 (en)
CA (1) CA2506686A1 (en)
WO (2) WO2004048536A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646990B2 (en) 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ Methods and compositions for stem cell self-renewal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
GB9608937D0 (en) * 1996-04-29 1996-07-03 Cancer Res Campaign Tech Screening methods for therapeutics and peptides used in the screen
EP1054969A2 (en) * 1998-02-12 2000-11-29 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIN ET AL.: "Analysis of mutationally altered forms of the Cct6 subunit of the Chaperonin from saccharomyces cerevisiae", GENETICS, vol. 147, December 1997 (1997-12-01), pages 1609 - 1633, XP008049764 *
SCHILLER E. ET AL.: "Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate B1 tubulin is decreased in Alzheimer's disease", LIFE SCIENCES, vol. 69, 2001, pages 263 - 270, XP002988099 *

Also Published As

Publication number Publication date
AU2003294501A1 (en) 2004-06-18
AU2003294501B2 (en) 2010-05-13
EP1578945A2 (en) 2005-09-28
WO2004048536A3 (en) 2004-08-19
WO2004048536A2 (en) 2004-06-10
WO2004048541A2 (en) 2004-06-10
EP1578945A4 (en) 2006-09-27
JP4646631B2 (en) 2011-03-09
AU2003294499A8 (en) 2004-06-18
AU2003294499A1 (en) 2004-06-18
JP2006507005A (en) 2006-03-02
CA2506686A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099047A3 (en) PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2004067722A3 (en) Facls as modifiers of the rb pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003294501

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003789986

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2506686

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004555682

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003789986

Country of ref document: EP